LIMN

Liminatus Pharma, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$2.77

Price (1 Year)

$92 $2.54

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %1.9 / %30
Non-compliant assets / Total market cap %0 / %30
Non-compliant revenue / Total income %100 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.

Website

Analysis (Turkish): LIMN Hissesi Caiz mi, Helal mi? Liminatus Pharma, Inc. Katılım Analizi